PARADISE-MI Secondary Prevention Algorithm

Clinical calculation support · Verify results before clinical use

Clinical decision-support aid for reviewing whether a recent myocardial infarction resembles the PARADISE-MI trial population and for organizing secondary-prevention considerations. It does not calculate an individualized treatment effect.

Patient and index-event profile

Enter information from the index acute myocardial infarction (AMI).

Clinical profile
Use LVEF associated with the index MI.
Use screening value when available. Leave blank if unknown.
Transient pulmonary congestion during index MI requiring IV treatment?
Killip class III or IV is one of the trial's risk-enhancing factors.
STEMI without reperfusion therapy within 24 hours after presentation?
Diabetes mellitus?
Atrial fibrillation associated with index MI?
Prior myocardial infarction before the index event?
Known history of heart failure before index MI?
PARADISE-MI enrolled patients without a known history of HF.
The trial randomized patients approximately 0.5–7 days after presentation. This is contextual, not a treatment deadline.

About PARADISE-MI

PARADISE-MI compared sacubitril/valsartan with ramipril in patients with a recent acute MI complicated by LVEF ≤40%, transient pulmonary congestion requiring treatment, or both, plus at least one prespecified risk-enhancing factor. The trial's primary endpoint was not significantly reduced with sacubitril/valsartan versus ramipril.

Risk-enhancing factors used in this tool

FactorTrial criterion
Age≥70 years
Renal functioneGFR <60 mL/min/1.73 m²
DiabetesDiabetes mellitus present
Prior MIPrevious myocardial infarction
Atrial fibrillationAssociated with index MI
LVEF<30%
Killip classClass III or IV
STEMI without reperfusionNo reperfusion within 24 hours

Interpreting the result

The tool reports whether the entered data satisfy the core profile and at least one risk-enhancing factor. It does not establish that the patient met every trial inclusion/exclusion criterion, predict the benefit of ARNI, or prescribe a drug.

Clinical context

After MI, secondary prevention should be individualized according to coronary anatomy, revascularization, bleeding and ischemic risk, LV function, comorbidities, and current guidelines.

  • Use evidence-based lipid-lowering therapy and reassess LDL-C to guide intensification.
  • Choose antiplatelet and, when indicated, anticoagulant therapy according to ACS context, thrombotic risk, and bleeding risk.
  • Address blood pressure, smoking, physical activity, diet, adherence, and cardiac rehabilitation.
  • For established HFrEF, implement guideline-directed therapy as tolerated and indicated, including renin–angiotensin system inhibition/ARNI, evidence-based beta-blocker, MRA, and SGLT2 inhibitor as appropriate.
  • Do not infer ARNI superiority after MI from PARADISE-MI alone. For established HFrEF, apply the relevant HF guideline and individual clinical context.
Safety note: If changing from an ACE inhibitor to sacubitril/valsartan, allow at least a 36-hour washout. Review blood pressure, renal function, potassium, angioedema history, pregnancy potential, and product-specific contraindications.

References

1. Pfeffer MA, Claggett B, Lewis EF, et al. Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction.New England Journal of Medicine. 2021;385:1845–1855. Primary PARADISE-MI outcomes and trial population. doi:10.1056/NEJMoa2104508
2. Jering KS, Claggett B, Pfeffer MA, et al. Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics.European Journal of Heart Failure. 2021;23(6):1040–1048. Trial design and enrollment characteristics. doi:10.1002/ejhf.2191 · PubMed
3. European Society of Cardiology. 2023 ESC Guidelines for the management of acute coronary syndromes.European Heart Journal. 2023;44(38):3720–3826. Guideline publication · ESC guideline page
Clinical disclaimer: This educational tool is intended to support, not replace, clinical judgment. It does not provide a diagnosis, individualized risk estimate, or prescription. Confirm the complete trial protocol and current local guidelines before making treatment decisions.